12,372 trials
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 72.4; 72.2 percentage of participants
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12) — 93.5; 91.8 Percentage of participants
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
Kidney Transplantation
Primary: GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen — 63.03; 68.59; 63.08 ml/min/1.73m² — p=< 0.0001
Non Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) — 14.9; 17.3; 8.2; 10.4 Months — p=0.00024
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002
Prostate Cancer
Primary: Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168. — 98.1 percentage of participants
Osteoarthritis of the Knee
Primary: Change From Baseline on the Brief Pain Inventory (BPI) 24-Hour Average Pain Score — -2.57; -1.80 units on a scale — p=<.0001
Myasthenia Gravis
Primary: Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years — 6.15; 8.99 units on a scale
Asthma · Wheezing
Primary: Exacerbation Frequency — 0.81; .87 asthma exacerbations per 46 weeks — p=0.67
Postpartum Weight Retention
Primary: Body Mass Index (BMI) — 33.62; 28.03; 26.90; 26.99 kg/m^2